Cosentyx (secukinumab) is a human monoclonal antibody that selectively binds to and inhibits interleukin-17A (IL-17A). IL-17A is a naturally occurring cytokine that is involved in inflammatory and immune responses. Cosentyx was developed by Novartis Pharmaceuticals and was approved by the U.S. Food and Drug Administration (FDA) in 2015 for the treatment of moderate to severe plaque psoriasis in...
The global Cosentyx Drug Market is estimated to be valued at USD 5.32 Bn in 2024 and is expected to exhibit a CAGR of 7.4% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Conducting a PEST analysis offers a comprehensive understanding of the external factors influencing the Cosentyx Drug Market. Politically, regulatory...
The Cosentyx drug market is mainly driven by the growing prevalence of psoriasis and psoriatic arthritis globally. Cosentyx is a human monoclonal antibody used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It works by selectively binding to interleukin-17A (IL-17A), preventing it from inducing inflammation. Cosentyx provides long-lasting relief...
The Cosentyx Drug Market has witnessed exponential growth in recent years, driven by a confluence of factors shaping its trajectory. A significant market driver is the escalating prevalence of autoimmune diseases globally. Conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis have become increasingly common, necessitating effective treatment options like Cosentyx. This...
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Romaian